Press Release

Covidien Announces Launch of AccuMesh™ Positioning System

Innovative Endomechanical Device Facilitates Insertion, Deployment and Placement of Mesh in Laparoscopic Ventral Hernia Repair

NEW YORK--(BUSINESS WIRE)--Mar. 29, 2012-- Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of the AccuMesh™ positioning system. This innovative endomechanical device facilitates insertion, deployment and placement of Parietex™ optimized composite (PCOx) mesh during minimally invasive ventral hernia repair procedures.

The AccuMesh positioning system adds to Covidien’s comprehensive, evidence-backed hernia care product portfolio, which includes advanced mesh products, the PermacolTM Surgical Implant and fixation and dissection products.

“Success of a laparoscopic ventral hernia repair is largely dependent on achieving a consistent 3 cm to 5 cm overlap between the mesh and the edge of the defect,” said Dean J. Mikami, MD, Assistant Professor of Surgery at Ohio State University Medical Center. “Accurately positioning the mesh relative to the defect using current techniques is considered one of the most difficult mesh-related steps in the procedure.”

With its expandable frame and precise articulation control, the AccuMesh positioning system is designed to deliver improved accuracy and faster operative time compared to traditional laparoscopic ventral hernia repair methods.

“Covidien continues to be a market leader through the expansion of its comprehensive, innovative hernia care portfolio,” said Paul Hermes, Vice President, Chief Technology Officer, Covidien Surgical Solutions. “During new product development, we strive to consistently address the issues that matter most to surgeons when delivering optimal patient care. The AccuMesh positioning system adds to our existing product innovations that include ProGrip™ self-gripping mesh, the only self-gripping, semi-resorbable, lightweight mesh available for hernia repair, and Parietex Composite (PCO) mesh, the first mesh to offer a resorbable collagen barrier on one side to limit visceral attachments during ventral hernia repair.”

The AccuMesh positioning system is designed for use with PCOx mesh, the next generation of PCO mesh, engineered to better address surgeon and patient needs in laparoscopic ventral hernia repair. The new design incorporates a more resistant barrier and a proprietary textile design with better visibility and increased strength. PCOx mesh promotes rapid abdominal wall integration1, minimizes visceral attachments1 and facilitates strong tack fixation.

The AccuMesh positioning system will soon be available as part of the overall Covidien hernia care product portfolio.

The AccuMesh positioning system, PCOx mesh and Covidien’s latest other innovations in hernia repair are on display at the 5th International Hernia Congress and American Hernia Society Joint Meeting, which is taking place at the Marriott Marquis in New York City from March 28 to March 31, 2012 (Booth #302/304).

About Ventral Hernias

Ventral hernias typically occur at the site of a previous surgical incision where the abdominal muscles have weakened. The inner lining of the abdomen pushes through the weakened area of the abdominal wall to form a balloon-like sac. This can allow a loop of intestines or other abdominal contents to push into the sac. If the abdominal contents get stuck within the sac, they can become trapped and this could lead to potentially serious problems that might require emergency surgery.

It is estimated that surgeons performed 900,000 ventral hernia repairs worldwide during 2011, and an estimated 350,000 of these procedures were performed in the US.2


Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

1 Evaluation of the Local Tissue Effects and Tissue Attachment Minimization in a Rat Caecal Adhesion Model. BioMatechTM (NAMSA), France (Feb. 2011).

2 Thomson Reuters MarketScan® Research Data, Thomson Reuters (Healthcare) Inc., at (accessed May 25, 2011).

Source: Covidien Covidien

Marta Newhart, 303-476-7383
Vice President
Communications & Public Affairs
Bruce Farmer, 508-452-4372
Vice President
Public Relations
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
Todd Carpenter, 508-452-4363
Investor Relations